NCI’s cancer screening trials may be falling victim to the COVID-19 pandemic.
An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.
NCI will form an ad hoc committee to review screening trials
The future of ECOG-ACRIN's slowly-accruing TMIST is in question
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
With NCI funding expected to remain flat through fiscal year 2025, health professionals and leaders in oncology should use this time to amp up institutional efforts to collaborate and rebuild trust in science, NCI Director Kimryn Rathmell said.
To address inequities in cancer health, NCI is collaborating with a diverse team of experts and cancer center directors—named the Cancer Equity Leaders (CEL)—to learn from communities and inform workforce development as well as outreach initiatives.
Sporting a leprechaun’s hat and a giant green bowtie, Matthew Huesser, DBA, conference chairperson and vice president for cancer research administration at the Sidney Kimmel Cancer Center at Thomas Jefferson University, welcomed over 400 attendees to Philadelphia for the inaugural meeting of the Association of Cancer Center Administrators.
A renowned surgeon and international authority on breast cancer, American College of Surgeons Past-President Edward (Ted) M. Copeland III, died on March 31 at the age of 86.
In 2013, the American College of Surgeons conducted an oral history interview with former ACS president Edward M. Copeland III.
